WVE-006 produces AAT protein at disease-protective levels in all treated patients. The monthly dosing regimen is under study, with more data expected in Q1 2026. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day Special ) Wave Life Sciences Ltd.

Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 ( 11.9 µM total ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. TD Cowen analyst Ritu Baral initiated coverage on Akero Therapeutics, Inc.

Wave Life Sciences ( NASDAQ:WVE ) , a clinical-stage biotechnology company focused on RNA-based medicines, reported second-quarter earnings on July 30, 2025, for the period ending June 30. The company missed Wall Street expectations by a wide margin, delivering revenue of $8.7 million for Q2 2025 ...

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.90% and -31.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients. multi-dosing is complete in first cohort ( 200 mg ) and single dosing is complete in second ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Ascendiant Capital analyst Edward Woo initiated coverage on Alarum Technologies Ltd.